Vol 71, No 2 (2020)
Clinical vignette
Published online: 2020-04-15
Difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder
1
, 1, 12, 12, 12
, 1, 12, 12, 12
Abstract
Not required for Clinical Vignette.
Keywords: paragangliomabladderimaging68Ga-DOTATATE PET/CTPRRT
References
- Zhai H, Ma X, Nie W, et al. Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center. Clin Genitourin Cancer. 2017; 15(5): e765–e771.
- Asa SL, Ezzat S, Mete O. The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. J Clin Med. 2018; 7(9).
- Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016; 43(10): 1784–1791.
- Satapathy S, Mittal BR, Bhansali A. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf). 2019; 91(6): 718–727.
- Botling J, Lamarca A, Bajic D, et al. High-grade progression confers poor survival in pancreatic neuroendocrine tumors. Neuroendocrinology. 2019 [Epub ahead of print].
